SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-180903
Filing Date
2020-06-26
Accepted
2020-06-26 16:03:14
Documents
13
Period of Report
2020-06-23
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d938886d8k.htm   iXBRL 8-K 43690
2 EX-3.1 d938886dex31.htm EX-3.1 5711
  Complete submission text file 0001193125-20-180903.txt   179547

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cbay-20200623.xsd EX-101.SCH 3067
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20200623_lab.xml EX-101.LAB 18890
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20200623_pre.xml EX-101.PRE 11858
15 EXTRACTED XBRL INSTANCE DOCUMENT d938886d8k_htm.xml XML 3566
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 20994082
SIC: 2834 Pharmaceutical Preparations